Evaluasi Penggunaan Ramipril dan Candesartan pada Pasien Rawat Inap COVID-19 dengan Komorbid Hipertensi di RSUD Dr. Moewardi

Deva Yolanda Dwi Nur Azizah; Tri Wijayanti; Lukito Mindi Cahyo

doi:10.22435/jki.v13i1.6064

Deva Yolanda Dwi Nur Azizah Program Studi Farmasi, Fakultas Farmasi, Universitas Setia Budi, Surakarta, Indonesia
Tri Wijayanti Program Studi Farmasi, Fakultas Farmasi, Universitas Setia Budi, Surakarta, Indonesia
Lukito Mindi Cahyo Program Studi Farmasi, Fakultas Farmasi, Universitas Setia Budi, Surakarta, Indonesia

DOI: https://doi.org/10.22435/jki.v13i1.6064

Keywords: COVID-19, Hypertension, Inpatient, Ramipril, Candesartan

Abstract

Hypertension is the most common comorbid in patients infected by COVID-19. Drugs often given for the treatment of hypertension, namely ramipril, and candesartan, are thought to increase the development of COVID-19 because the angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) increase the expression of ACE-2, which is the binding site of SARS-CoV-2. This study aims to analyze the effect of using ramipril and candesartan on healing in hospitalized patients with COVID-19 with hypertension at RSUD dr. Moewardi in 2020. This study was conducted retrospectively. The results were presented descriptively and used medical record data of hospitalized patients with COVID-19 with comorbid hypertension at RSUD dr. Moewardi in 2020. Using ramipril and candesartan affects patient recovery in terms of length of stay (LOS), symptom relief, and RT-PCR test results. Analysis of the research data using SPSS with Spearman correlation test. The Spearman correlation test showed that there was a fairly strong relationship between the use of ramipril and candesartan in patients with COVID-19 with comorbid hypertension on LOS, symptom relief, and RT-PCR test results. The study results show that using ramipril and candesartan can improve the recovery of patients with COVID-19 with comorbid hypertension. ACEI and ARB drugs have not been proven to worsen the patient's condition so their use can be continued.

References

Gugus Tugas COVID-19. Peta sebaran gugus tugas percepatan penanganan COVID-19 [Internet]. 2020 [disitasi 5 Jun 21]. Diperoleh dari :https://covid19.go.id/

peta-sebaran

Linelejan B, Umboh O, Wantania FE. Pengaruh penggunaan angiotensin converting enzyme inhibitor (ACEI) dan angiotensin receptor blocker (ARB) pada pasien coronavirus disease 2019 (covid-19) dengan hipertensi. e-CliniC. 2021;9(1):104-9.

Guan W, Zheng-yi Ni, Yu Hu, Liang W, Ou C, He J. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708–20. doi: 10.1056/NEJMoa2002032

Wang, Qiang W, Ke Hu. A handbook of 2019-nCoV pneumonia control and prevention. Hubei Science and Technology Press. China. 2020;33-40

Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS- CoV-2 in Wuhan , China. Europian Journal of Allergy and Clinical Immunology. 2020 Jul;75(7): 1730-41.doi: 0.1111/all.1423

Bwire GM. Coronavirus: Why men are more vulnerable to Covid-19 than women?. SN Compr Clin Med. 2020; 2(7): 874–876. doi:10.1007/s42399-020-00341-w

WHO. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. interim guidance [Internet]. 2020 [disitasi 10 Jun 21]. Diperoleh dari:https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1

Kemenkes RI. Cara efektif cegah penularan COVID-19 : Pemeriksaan, pelacakan, karantina, dan isolasi. Kementrian Kesehatan RI [Internet]. 2021 [disitasi 5 Jun 21]. Diperoleh dari : https://sehatnegeriku.kemkes.go.id/

Wang, Zhao X, Wei W, Fan W, Gao K, He S, Zhuang X. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients. BMC Infect Dis. 2021;21(1):1-8. doi: 10.1186/s12879-021-05821-5

Yan F, Huang F, Xu J. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discovery 2020;6(1):77. doi : 10.1038/s41421-020-00221-6

Burhan E, Dwi Susanto A, Isbaniah F, Aman Nasution S, Ginanjar E, Wicaksono Pitoyo C, et al. Pedoman tatalaksana COVID-19. Jakarta; 2020

Suryantoro SD, Thaha M, Hayati MR, Yusuf M, Pikir BS, Susilo H. Correlation between anti-hypertensive drugs and disease progression among moderate, severe, and critically ill COVID-19 patients in the second referral hospital in Surabaya: A retrospective cohort study. F1000Research. 2021:1-20. doi: 10.12688/f1000research.51785.2

Azwar MK, Setiati S, Rizka A, Fitriana I, Saldi SRF, Safitri ED. Clinical profile of elderly patients with COVID-19 hospitalised in Indonesia's National General Hospital. Acta Med Indones. 2020; 52(3): 199-205. PMID: 33020331

Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020; 383(23): 2255-2273.doi: 10.1056/NEJMra2026131

Lam KW, Chow KW, Vo J, Hou W, Li H, Richman PS, et al. Continued in-hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis. 2020; 222(8): 1256-1264. doi: 10.1093/infdis/jiaa447

Semenzato L, Botton J, Drouin J, Baricault B, Vabre C, Cuenot F, et al. Antihypertensive drugs and COVID-19 risk : A cohort study of 2 million hypertensive patients. American Heart Association Journal. 2021; 77: 833–842.

doi:10.1161/HYPERTENSIONAHA.120.16314

World Health Organization. Pertanyaan dan Jawaban Terkait Coronavirus [Iinternet]. 2020. [disitasi 5 Jun 21]. Diperoleh dari : https://www.who.int/indonesia/news/novel-coronavirus/qa/qa-for-public

European Society of Cardiology. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. European Heart Journal. 2021; 00: 1–45. doi: 10.1093/eurheartj/ehab697Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223) :497-506 doi: 10.1016/S0140-6736(20)30183-5

Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clin Infect Dis. 2020;71(15):889-90. doi: 10.1093/cid/ ciaa330

Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020;116(10):1688-99. doi: 10.1093/cvr/cvaa097

Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Am J Hypertens. 2020;33(5):373-74. doi: 10.1093/ajh/hpaa057

Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:47-56. doi: 10.1016/j.ijid.2020.07.029